

TORREYA EUROPE:

A Global Investment Bank Serving
Life Sciences Companies

REPRESENTATIVE TRANSACTIONS SINCE 2015

Over \$100 Billion
in Deals Closed
Across Nearly
250 Assignments
Since Inception

- Mergers & Acquisitions
- Pharmaceutical Asset Sales
- Capital Markets
- Licensing Deals


 licensing of ex European rights to LYS-SAF302 to \$15 million upfront with up to \$110m in additional payments plus royalties October 2018	 Licensing Agreement for Feraccru® in Europe, Australia and New Zealand with £11 million upfront (and up to €54.5m in milestones, + 25%-40% royalties on net sales) September 2018	 Proposed Sale of Midatech Pharma US Inc. to Kanwa Holdings LP, an affiliate of Barings LLC Up to \$19 million September 2018	 Partial royalty monetization with \$7.5 million June 2018
 Sale of Yargesa to June 2018	 Loan Agreement with \$15 million January 2018	 Company sale to \$15 million June 2017	 Sale of Intrathecal business to \$203 million March 2017
 Collaboration agreement for Emricasan with \$50 million upfront December 2016	 Company sale to > €75 million November 2016	 Financial advisor in private placement €100 million May 2016	 Sale of FXR program to €470 million January 2015

LEADING ADVISOR ON GLOBAL PHARMA TRANSACTIONS OF \$10 MILLION – \$1 BILLION, 2015 – 2017

Personal Relationships, Operating Perspective, Life Sciences Focus Make Torrey a an Advisor of Choice in Europe

- Team of 8 professionals with more than 150 years of combined experience
- Expertise in biotechnology, branded pharmaceuticals, generic pharmaceuticals, and life sciences
- Deep knowledge of marketplace and players; executive-level relationships across sectors
- Serving clients' long-term interests: multiple transactions for many clients

% of pharma transactions with Torrey involvement¹



¹ Global M&A and Asset-based deals over \$10 million in value, 2008 – 2017 where any financial advisor was used

TORREYA.COM
NEW YORK | LONDON | MUMBAI

For more information, please contact +44 (0) 207 451 4550

Securities offered in the United States are offered through Torrey Capital LLC, Member FINRA/SIPC.

In Europe, such services are offered through Torrey Partners (Europe) LLP, which is authorised and regulated by the UK Financial Conduct Authority.